Efficacy of BBG-01 (Bifidobacterium breve) on pre and postoperative infectious complications of infants in Juntendo University Hospital - Efficacy of BBG-01 administration for infants

Division of Laboratory for Probiotic Research, Juntendo University0 个研究点目标入组 30 人开始时间: 2011年3月3日最近更新: 2023年10月17日

适应症

试验速览

阶段: 未知
状态: 招募中
发起方
入组人数: 30

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

BBG-01 was well tolerated without adverse effects, and postoperative infectious complications were significantly decreased. Fecal analysis showed increased Bifidobacterium and decreased Enterobacteriaceae, Clostridium difficile, and Pseudomonas. Concentrations of fecal acetic acid were significantly increased, maintaining fecal pH at <7.0. The incidence of detecting bacteria in blood was significantly reduced.

研究设计

研究类型: Interventional

入排标准

年龄范围: ot applicable 至 15years-old（—）
性别: All

入选标准

未提供

排除标准

•- A subject who cannot ingest the test diet due to intestinal dysfunction. - A subject whose operation is cancelled. - A subject who is not suitable for the trial defined by the attending researcher.

研究者

发起方

Division of Laboratory for Probiotic Research, Juntendo University

相似试验

招募中

不适用

Efficacy of early administration of BBG-01 (Bifidobacterium breve) on growth and development of preterm infants in NICvery low birth weight (VLBW) infants and extremely low birth weight (ELBW) infants

JPRN-UMIN000005412Division of Laboratory for Probiotic Research, Juntendo University,200

尚未招募

不适用

Effects of Bifidobacterium breve (BBG-01) administration in Neonatal Intensive Care Unit cared preterm infants to gain enterobacterial flora

JPRN-UMIN000023354Ehime University Graduate School of Medicine20

招募中

不适用

Efficacy of Bifidobacterium Agent on Patients with Irritable Bowel Syndrome: A Randomized Controlled TrialIrritable Bowel SyndromeChronic Diseases, FunctionalC06.405.469.158.272.608

JPRN-jRCTs021210038Fukudo Shin70

招募中

3 期

A clinical trial to determine whether prophylatic administration of Probiotic Bifidobacterium breve to preterm infants reduces the incidence of episodes of Late onset sepsis

CTRI/2019/04/018393ational Health Mission

已完成

1 期

Clinical Study to Investigate the Safety and Tolerance of Therapeutic BCG in Postoperative Adjuvant Therapy in Subjects With Moderate to High-risk Non-muscular Invasive Bladder Cancer (NMIBC)Non-muscular Invasive Bladder Cancer

NCT06350838Chengdu CoenBiotech Co., Ltd10